Bryan

Vulcan Blockchain's Auto-Staking Revolution - Exploring the Solution to the SEC's Staking Ban

Retrieved on: 
Thursday, February 16, 2023
Bryan, Coinbase, Safety, Decentralized finance, Blockchain, FTX, Cryptocurrency, Kraken

In this context, Vulcan Blockchain emerges as a viable solution through its breakthrough Auto-Staking innovation.

Key Points: 
  • In this context, Vulcan Blockchain emerges as a viable solution through its breakthrough Auto-Staking innovation.
  • Overall, the SEC's staking ban, which restricts cryptocurrency exchanges from offering staking services for certain securities-like cryptocurrencies, was introduced following the shutdowns of platforms such as Terra Luna and FTX.
  • On 8 February 2023, Coinbase CEO Brian Armstrong raised the alarm about widespread rumors of a possible ban on crypto staking.
  • Created by renowned blockchain expert Bryan Legend, Vulcan Blockchain is quickly gaining attention for its revolutionary approach to the staking process.

The Laserfiche Solution Marketplace Accelerates Enterprise Innovation and Digital Transformation ROI

Retrieved on: 
Wednesday, June 8, 2022
Professional Services, Data Management, Other Professional Services, Technology, Other Technology, Software, Internet, Software, Environment, Government, Record, Organization, Bryan Independent School District, Solution, Multimedia, Machine learning, Growth, Student, Technology, Industry, Bryan, Health, Software as a service, Education, Automation, Online shopping, Management, Laserfiche

Laserfiche the leading SaaS provider of intelligent content management and business process automation has launched the Laserfiche Solution Marketplace , a publicly-accessible collection of solution templates to help jumpstart process automation and digital transformation.

Key Points: 
  • Laserfiche the leading SaaS provider of intelligent content management and business process automation has launched the Laserfiche Solution Marketplace , a publicly-accessible collection of solution templates to help jumpstart process automation and digital transformation.
  • View the full release here: https://www.businesswire.com/news/home/20220608005029/en/
    The Laserfiche Solution Marketplace helps organizations address digital transformation needs and accelerate innovation enterprise-wide by taking a low-code approach to process automation and integration.
  • The Laserfiche Solution Marketplace currently contains more than 100 solution templates that address both common business processes and individual industry or organization needs.
  • To learn more about solution templates and how to submit your own, visit the Laserfiche Solution Marketplace: https://marketplace.laserfiche.com/ .

Elementus Expands Leadership Team With Hires From Amazon, JPMorgan, and Global Relay

Retrieved on: 
Thursday, April 7, 2022
Crypto, List of Amazon products and services, Avenger, Trust, FTX, NEW, JPMorgan Chase, Blockchain, Investment banking, Data science, Growth, Bryan, Head, Fiserv, Gemstone, Meta, Fidelity, Facebook, Global Relay, Baird (investment bank), AWS, Efficiency, Finix Comics, Cryptocurrency, Management, Amazon, Engineering, Operation, Palantir Technologies

NEW YORK, April 7, 2022 /PRNewswire/ -- Elementus, the leading blockchain/crypto analytics platform, has expanded its leadership team with strategic hires from Amazon, JPMorgan, and Global Relay.

Key Points: 
  • The Blockchain/Crypto Analytics Firm Welcomes Sirish Jetti, Bryan Young, and Matt Austin
    NEW YORK, April 7, 2022 /PRNewswire/ -- Elementus, the leading blockchain/crypto analytics platform, has expanded its leadership team with strategic hires from Amazon, JPMorgan, and Global Relay.
  • At Elementus, Sirish will lead the company's engineering and data science teams as they develop the next generation of blockchain analytics tools.
  • "I am thrilled to join one of the most exciting startups in the blockchain space," says Sirish Jetti.
  • "I couldn't be more excited to join Elementus' growing team of innovators committed to transparency in the blockchain sector."

BRYAN BROTHERS SERVE UP 'RACQUETS FOR REFUGEES' FUNDRAISING AUCTION IN SUPPORT OF ELINA SVITOLINA'S EFFORTS FOR UKRAINE

Retrieved on: 
Thursday, March 3, 2022
Omni, Brothers, Bullying, Love, Bryan brothers, ACE, Program, Tennis, Exhibition, Bryans, Bryan, CA, Marriage, 2013 BNP Paribas Open, Bush, ATP, Refugee, Organic, BNP Paribas, WTA, Star, Online gambling, Sports equipment, Counsel

INDIAN WELLS, Calif., March 3, 2022 /PRNewswire/ -- Bob and Mike Bryan announced today that they will launch a 'Racquets for Refugees' fundraising auction during the BNP Paribas Open March 8 -20 in support of Elina Svitolina's efforts to provide humanitarian aid to Ukrainian refugees. 

Key Points: 
  • The Bryans have made several trips to Texas to support the work of the Bush ACE Outreach Program.
  • In 2018, WTA star Elina Svitolina visited West Texas to support the program and after seeing the program in action decided to launch her own foundation.
  • "The Bush ACE Outreach Program has been blessed to have the support of Bob and Mike Bryan and Elina Svitolina and we are proud to help Elina's programs in Ukraine.
  • "It has been a pleasure to support Elina Svitolina and her foundation over the years,"said Cliff Drysdale.

BRYAN BROTHERS SERVE UP 'RACQUETS FOR REFUGEES' FUNDRAISING AUCTION IN SUPPORT OF ELINA SVITOLINA'S EFFORTS FOR UKRAINE

Retrieved on: 
Thursday, March 3, 2022
Omni, Brothers, Bullying, Love, Bryan brothers, ACE, Program, Tennis, Exhibition, Bryans, Bryan, CA, Marriage, 2013 BNP Paribas Open, Bush, ATP, Refugee, Organic, BNP Paribas, WTA, Star, Pharmaceutical industry, Online gambling, Sports equipment, Counsel

The Bryans have made several trips to Texas to support the work of the Bush ACE Outreach Program.

Key Points: 
  • The Bryans have made several trips to Texas to support the work of the Bush ACE Outreach Program.
  • In 2018, WTA star Elina Svitolina visited West Texas to support the program and after seeing the program in action decided to launch her own foundation.
  • "The Bush ACE Outreach Program has been blessed to have the support of Bob and Mike Bryan and Elina Svitolina and we are proud to help Elina's programs in Ukraine.
  • "It has been a pleasure to support Elina Svitolina and her foundation over the years,"said Cliff Drysdale.

iBio Announces Partial Adjournment of Annual Meeting to December 22

Retrieved on: 
Friday, December 10, 2021
Patient, COVID-19, 2015 Michigan Proposal 1, SEC, Marketing, Sale, NYSE American, Vaccine, Annual general meeting, Hydroponics, Annual report, CEO, Glycosylation, Maintenance, FOR, CDMO, GLOBE, NYSE, Research, Company, Compliance, Annual Meetings of the International Monetary Fund and the World Bank Group, Growth, Antigen, Exercise, Protein, Infection, Annual, ISS, Cancer, Glass Lewis, Holding company

BRYAN, Texas, Dec. 10, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPharming Manufacturing System®, today announced that its annual meeting of stockholders (the "Annual Meeting") scheduled for and convened yesterday has been partially adjourned to December 22, 2021 at 9:00 a.m. Eastern Time.

Key Points: 
  • The Companys stockholders also approved Proposal 6 (adjournment of the Annual Meeting) for the purpose of continuing to solicit votes in favor of Proposal 4 (reverse stock split) and Proposal 5 (authorized share decrease).
  • With over 60% of all shares voted, iBio stockholders are in favor of the reverse split and authorized share decrease by approximately a 2-to-1 margin.
  • Additionally, both of the leading proxy advisory firms (Glass Lewis and ISS) have recommended that stockholders vote FOR the proposals.
  • iBio is developing proprietary biopharmaceuticals for the treatment of cancers, as well as fibrotic and infectious diseases.

ISS Joins Glass Lewis in Recommending Shareholders Vote “FOR” All Proposals Ahead of iBio’s Upcoming Annual Meeting

Retrieved on: 
Tuesday, November 30, 2021
Sale, CEO, Cancer, Protein, Annual report, Company, NYSE, Glass Lewis, Compliance, Antigen, Glycosylation, Hydroponics, RET, NYSE American, SEC, Shareholder, ISS, Investor, Vaccine, COVID-19, U.S. Securities and Exchange Commission, Annual general meeting, Research, Chief executive officer, Communication, GLOBE, LLC, Marketing, Board, Institutional Shareholder Services, Infection, Maintenance, CDMO, Growth, Holding company, Internet service provider, Security (finance)

BRYAN, Texas, Nov. 30, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPharming Manufacturing System®, today announced that Institutional Shareholder Services, Inc. (“ISS”) has joined Glass Lewis and Co., LLC (“Glass Lewis”) in recommending that the Company’s stockholders vote “FOR” all proposals put forth in the definitive proxy statement prior to its Annual Meeting of Stockholders to be held on December 9, 2021.

Key Points: 
  • The voting recommendations of ISS and Glass Lewis are relied upon by institutional investment firms, mutual funds, and other fiduciaries globally for independent advice on shareholder voting and corporate governance.
  • Neither firm has any business relationship with iBio, and iBio did not engage or compensate them for their analyses or recommendations.
  • This communication may be deemed to be solicitation material in connection with the proposals to be considered at iBios 2021 Annual Meeting of Stockholders.
  • These forward-looking statements are based upon current estimates and assumptions and include statements regarding the anticipated effects of stockholder approval of matters to be voted on at iBios 2021 annual meeting of stockholders (the "Annual Meeting").

Omicron Variant Underscores Need for New COVID Vaccine Candidates Like IBIO-202

Retrieved on: 
Monday, November 29, 2021
Dai, Capsid, Sale, Regulation of tobacco by the U.S. Food and Drug Administration, Cancer, Protein, Virus, Â, Access, BioRxiv, Company, COVID-19 vaccine, WHO, World, Severe acute respiratory syndrome coronavirus 2, Glycosylation, Hydroponics, Injection, Agency, SEC, Vaccine, COVID-19, Virology, DVM, U.S. FDA, Research, DNA, GLOBE, Marketing, N, Identification, Public health, Epitope, Infection, John Huettner, CDMO, Food, COVID, Animal

BRYAN, Texas, Nov. 29, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming Manufacturing System®, today announced an update for its lead COVID-19 vaccine program, IBIO-202, in light of the emergence of the Omicron (B.1.1.529) variant of SARS-CoV-2.

Key Points: 
  • Second, the N protein is more highly conserved than the S protein, and therefore, new variants may be less likely to escape vaccine protection.
  • We are developing our COVID vaccine candidate in line with an approach we call our DAVi strategy, which stands for improved Durability, Access and Variant-inclusion.
  • Finally, we expect an N-based vaccine to provide better protection against future variants, given how mutable the S protein appears to be.
  • In November 2020, iBio made the decision to begin exploring a second-generation COVID vaccine program based upon the nucleocapsid protein.

Leading Independent Proxy Advisory Firm, Glass Lewis, Recommends iBio Shareholders Vote “FOR” All Proposals Ahead of Annual Meeting

Retrieved on: 
Wednesday, November 17, 2021
Sale, CEO, Cancer, Protein, Annual report, Company, Glass Lewis, NYSE, Compliance, Antigen, Glycosylation, Hydroponics, NYSE American, SEC, Shareholder, Investor, Vaccine, COVID-19, U.S. Securities and Exchange Commission, Annual general meeting, Research, Chief executive officer, Communication, GLOBE, LLC, Marketing, Infection, Maintenance, CDMO, Growth, Holding company, Security (finance)

Tom Isett, Chairman & CEO of iBio, commented, We greatly appreciate this third-party, independent recommendation from Glass Lewis.

Key Points: 
  • Tom Isett, Chairman & CEO of iBio, commented, We greatly appreciate this third-party, independent recommendation from Glass Lewis.
  • iBio urges stockholders to vote today to support our strategic growth plans.
  • This communication may be deemed to be solicitation material in connection with the proposals to be considered at iBios 2021 Annual Meeting of Stockholders.
  • Shareholders are urged to read the definitive proxy statement and all other relevant documents filed with the SEC because they contain important information about the proposals.

iBio Reports Fiscal First Quarter 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, November 15, 2021
CSF, Cancer, Industry, Therapy, University of Texas Southwestern Medical Center, Food, Growth, COVID-19, Artificial intelligence, Capsid, Tumor microenvironment, Regulation of tobacco by the U.S. Food and Drug Administration, Public expenditure, Webcast, U.S. Department of Defense Strategy for Operating in Cyberspace, Chief executive officer, CDMO, Ownership, Technology, Research, Injection, Element, Classical swine fever, GLOBE, Fiscal, Shareholder, Time, Marketing, Patient, Glycosylation, Compliance, Hydroponics, G&A, Investor, Infection, CEO, CGMP, Veterinary medicine, LLC, Sale, Protein, Vaccine, SEC, NYSE American, University, Maintenance, Government, University system, Investment, Partnership, Company, ESG, Awareness, Texas A&M University System, NYSE, IND, Fine chemical, Pharmaceutical industry, Animal

BRYAN, Texas, Nov. 15, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming Manufacturing System®, today announces its financial results for the fiscal quarter ended September 30, 2021 and provides a corporate update.

Key Points: 
  • BRYAN, Texas, Nov. 15, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (iBio or the Company), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming Manufacturing System, today announces its financial results for the fiscal quarter ended September 30, 2021 and provides a corporate update.
  • We are continuing to accelerate the execution of our growth strategy as we start our fiscal year 2022, said Tom Isett, Chairman & CEO of iBio.
  • Fiscal First Quarter and Recent Business Developments:
    In August 2021, iBio added to its pipeline by in-licensing an IL-2 sparing anti-CD25 antibody (IBIO-101) from RubrYc Therapeutics.
  • R&D and G&A expenses for the first quarter of fiscal 2022 increased 35% and 24%, respectively, over the comparable period in fiscal 2020.